TNSN06384A1 - Indazoles substitues, compositions les contenant, procede de fabrication et utilisation - Google Patents

Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Info

Publication number
TNSN06384A1
TNSN06384A1 TNP2006000384A TNSN06384A TNSN06384A1 TN SN06384 A1 TNSN06384 A1 TN SN06384A1 TN P2006000384 A TNP2006000384 A TN P2006000384A TN SN06384 A TNSN06384 A TN SN06384A TN SN06384 A1 TNSN06384 A1 TN SN06384A1
Authority
TN
Tunisia
Prior art keywords
manufacture
compositions containing
indazoles
containing same
substituted indazoles
Prior art date
Application number
TNP2006000384A
Other languages
English (en)
Inventor
Franck Halley
Michel Tabart
Herve Bouchard
Catherine Souaille
Brun Alain Le
Fabrice Viviani
Laurence Gauzy-Lazo
Pascal Desmazeau
Odile Angouillant-Boniface
Bruno Filoche-Romme
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34946329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TNSN06384A1 publication Critical patent/TNSN06384A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Indazoles substitués, compositions les contenant, procédé de fabrication et utilisation. La présente invention concerne en particulier de nouveaux indazoles substitués spécifiques présentant une activité inhibitrice de kinases, ayant une activité thérapeutique, en particulier en oncologie.
TNP2006000384A 2004-06-04 2006-11-24 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation TNSN06384A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406042A FR2871158A1 (fr) 2004-06-04 2004-06-04 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PCT/FR2005/001335 WO2006003276A1 (fr) 2004-06-04 2005-06-01 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
TNSN06384A1 true TNSN06384A1 (fr) 2008-02-22

Family

ID=34946329

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000384A TNSN06384A1 (fr) 2004-06-04 2006-11-24 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Country Status (22)

Country Link
US (1) US7517902B2 (fr)
EP (1) EP1765813A1 (fr)
JP (1) JP2008501669A (fr)
KR (1) KR20070043769A (fr)
CN (1) CN1980918A (fr)
AR (1) AR049389A1 (fr)
AU (1) AU2005259139B2 (fr)
BR (1) BRPI0510777A (fr)
CA (1) CA2567744A1 (fr)
CR (1) CR8767A (fr)
EA (1) EA012702B1 (fr)
EC (1) ECSP067046A (fr)
FR (1) FR2871158A1 (fr)
IL (1) IL179595A0 (fr)
MA (1) MA28664B1 (fr)
MX (1) MXPA06013954A (fr)
NO (1) NO20066050L (fr)
TN (1) TNSN06384A1 (fr)
TW (1) TW200610756A (fr)
UY (1) UY28941A1 (fr)
WO (1) WO2006003276A1 (fr)
ZA (1) ZA200610040B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102006005179A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
ES2509820T3 (es) * 2006-12-20 2014-10-20 Nerviano Medical Sciences S.R.L. Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
WO2009013126A1 (fr) 2007-07-20 2009-01-29 Nerviano Medical Sciences S.R.L. Dérivés d'indazole substitués actifs comme inhibiteurs de kinases
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
BR112012023021A2 (pt) * 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2016096709A1 (fr) 2014-12-16 2016-06-23 Eudendron S.R.L. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
WO2016160617A2 (fr) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
EP3347018B1 (fr) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
MX2018007266A (es) 2015-12-18 2018-11-09 Ignyta Inc Combinaciones para el tratamiento del cancer.
SG11201901146SA (en) 2016-09-23 2019-04-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
AU2017373758B2 (en) * 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
WO2019018562A1 (fr) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. Composé amido utilisés comme modulateurs du ahr
WO2019018570A1 (fr) 2017-07-19 2019-01-24 Ignyta, Inc. Compositions pharmaceutiques contenant de l'entrectinib
EP3697390A1 (fr) 2017-10-17 2020-08-26 Ignyta, Inc. Compositions pharmaceutiques et formes galéniques solides
CN109134451A (zh) * 2018-09-10 2019-01-04 遵义医学院 1,3-二取代脲类与硫脲类衍生物及其应用
WO2020210828A1 (fr) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza) indazolyl-aryle sulfonamide et composés apparentés et leur utilisation dans le traitement d'états médicaux
CN114276297A (zh) * 2020-10-15 2022-04-05 兰州大学 一种1h-吲唑vegfr-2激酶抑制剂及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003051847A1 (fr) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Derives de (1-h-indazol-3-yl) -amide comme inhibiteurs de gsk-3
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
BR0311291A (pt) * 2002-05-17 2005-03-29 Pharmacia Italia Spa Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos
AU2003259749A1 (en) 2002-08-12 2004-02-25 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
EP1537087B1 (fr) 2002-09-05 2012-11-28 Aventis Pharma S.A. Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
NZ541193A (en) * 2002-12-12 2009-01-31 Aventis Pharma Sa Aminoindazole derivatives and use thereof as kinase inhibitors
ES2346538T3 (es) * 2003-05-22 2010-10-18 Abbott Laboratories Inhibidores de quinasa de tipo indazol, benzisoxazol y benzisotiazol.
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
JP2008533032A (ja) 2005-03-10 2008-08-21 シージーアイ ファーマシューティカルズ，インコーポレイティド 或る種の置換アミド、その製造方法及び使用方法

Also Published As

Publication number Publication date
NO20066050L (no) 2007-02-05
TW200610756A (en) 2006-04-01
MXPA06013954A (es) 2007-03-15
JP2008501669A (ja) 2008-01-24
AU2005259139B2 (en) 2011-09-08
WO2006003276A1 (fr) 2006-01-12
ECSP067046A (es) 2006-12-29
US20070161626A1 (en) 2007-07-12
CR8767A (es) 2007-08-28
CA2567744A1 (fr) 2006-01-12
CN1980918A (zh) 2007-06-13
UY28941A1 (es) 2005-12-30
AR049389A1 (es) 2006-07-26
BRPI0510777A (pt) 2007-11-20
EA012702B1 (ru) 2009-12-30
EP1765813A1 (fr) 2007-03-28
MA28664B1 (fr) 2007-06-01
US7517902B2 (en) 2009-04-14
ZA200610040B (en) 2008-02-27
IL179595A0 (en) 2007-05-15
EA200602241A1 (ru) 2007-04-27
KR20070043769A (ko) 2007-04-25
FR2871158A1 (fr) 2005-12-09
AU2005259139A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
TNSN06384A1 (fr) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TNSN04175A1 (fr) Indazoles substitues avec une activite anticancereuse
TW200733453A (en) Method of using an electrochemical cell
FR10C0037I2 (fr) Composes chimiques
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2005028443A3 (fr) Inhibiteurs de l'enzyme de la proteine tyrosine kinase
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
DE60228103D1 (de) Chemische verbindungen
BRPI0409367A (pt) derivados de piperidina inibidores de renina
NO20041493L (no) Kjemiske forbindelser.
ATE554087T1 (de) Neue kinaseinhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
BRPI0414599A (pt) pirrol-indóis substituìdos
NO20091976L (no) Nye forbindelser
WO2007067781A3 (fr) Inhibiteurs de proteines kinases
ECSP045255A (es) Cumarinas utiles como biomarcadores
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
BRPI0512547A (pt) pirimidinas
WO2006072612A3 (fr) Triazolophthalazines
MA30972B1 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.